Skip to main content
Industry News
FDA grants priority review for zanubrutinib for MZL
5/21/2021

The FDA has granted priority review status to Chinese pharma company BeiGene for its application for Brukinsa, or zanubrutinib, a treatment for pretreated marginal zone lymphoma. The submission is supported by data from the company's midstage MAGNOLIA trial.

Full Story: